



1614

PTO/SB/21 (02-04)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

4

Application Number

AL01350Q

10/79/1477

Filing Date

03/02/2004

First Named Inventor

Harris

Art Unit

To Be Assigned

Examiner Name

To Be Assigned

Attorney Docket Number

AL01350Q

## ENCLOSURES (Check all that apply)

☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Information Disclosure Statement

☐

Certified Copy of Priority Document(s)

☐

Response to Missing Parts/Incomplete Application

☐

Response to Missing Parts under 37 CFR 1.52 or 1.53

☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐

Petition to Convert to a Provisional Application

☐

Power of Attorney, Revocation

☐

Change of Correspondence Address

☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s)

Remarks

☐

After Allowance communication to Group

☐

Appeal Communication to Board of Appeals and Interferences

☐

Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

☐

Proprietary Information

☐

Status Letter

☒

Other Enclosure(s) (please identify below):

References (5 documents); Return Post Card

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Robert J. Lipka, Reg. No. 42807

Signature

*Robert J. Lipka*

Date

March 23, 2004

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Robert J. Lipka, Reg. No. 42807

Signature

*Robert J. Lipka*

Date

March 23, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

AL01350Q



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X  
In re Application of:  
Harris et al.

: Examiner: TBA

For: TREATMENT METHODS

: Art Unit: TBA

Serial No.: TBA

Filed: 3/2/04  
-----X

Commissioner for Patents,  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. § 1.56, applicants hereby disclose the following information for consideration by the Examiner:

Each of the documents listed on accompanying PTO Form 1449 submitted herewith. A copy of each listed document is enclosed for the convenience of the Examiner, which copy is the best available to the Applicant at this time; the Examiner is requested to disregard any underlining or marginal notation (if any) appearing in a copy, since marking may have been done for another purpose and may not pertain in any manner to the subject application.

The listed documents may be relevant to examination of the application. Inclusion of the document is not an admission that the document is prior art with respect to the invention of the application and is not to be

**AL01350Q**


construed as an admission that anything in the document renders any claim of the application unpatentable.


Applicants assert that the claimed invention is patentable over the documents listed on PTO-1449.

The Examiner is kindly requested to initial and return the PTO-1449 Form to evidence consideration of these documents.

It is not believed that any fee is due. In the event a fee is due, the Commissioner is authorized to charge said fee to Deposit Account No. 19-0365.

Respectfully submitted,

  
Robert J. Lipka  
Reg. No. 42,807  
Registered Representative  
(908) 298-5056

Sheet 1 of 1

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: AL01350Q		SERIAL NO.: TBA	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT: HARRIS, et al.			
				FILING DATE: 03/02/2004		GROUP: TBA	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,767,115	06/16/98				
	AB	5,846,966	12/08/98				
	AC	RE37, 721 E	05/28/02				
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL						
	AM						
	AN						
	AO						
	AP						
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	AQ	Danesh, J., et al. Low grade inflammation and coronary heart disease: prospective study and update meta-analyses, BMJ, Vol 321, (July 2000), pp. 199-204.					
	AR	Sbarouni, E, et al. Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease, European Heart Journal Vol. 21, 12, (June 2000), pp. 975-980					
	AS						
	AT						
	AU						
	AV						
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							